OA10854A - Formulations pharmaceutiques à libération prolongée contenant de la mizolastine - Google Patents

Formulations pharmaceutiques à libération prolongée contenant de la mizolastine Download PDF

Info

Publication number
OA10854A
OA10854A OA9800160A OA9800160A OA10854A OA 10854 A OA10854 A OA 10854A OA 9800160 A OA9800160 A OA 9800160A OA 9800160 A OA9800160 A OA 9800160A OA 10854 A OA10854 A OA 10854A
Authority
OA
OAPI
Prior art keywords
mizolastine
sustained
formulation according
release
pharmaceutical
Prior art date
Application number
OA9800160A
Other languages
English (en)
French (fr)
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of OA10854A publication Critical patent/OA10854A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9800160A 1996-03-04 1998-09-04 Formulations pharmaceutiques à libération prolongée contenant de la mizolastine OA10854A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
OA10854A true OA10854A (fr) 2003-02-05

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800160A OA10854A (fr) 1996-03-04 1998-09-04 Formulations pharmaceutiques à libération prolongée contenant de la mizolastine

Country Status (35)

Country Link
US (2) US6165507A (ko)
EP (1) EP0906101B1 (ko)
JP (2) JP2000512617A (ko)
KR (1) KR100369888B1 (ko)
CN (1) CN1112929C (ko)
AR (1) AR006082A1 (ko)
AT (1) ATE219365T1 (ko)
AU (1) AU725494B2 (ko)
BG (1) BG63451B1 (ko)
BR (1) BR9707827A (ko)
CA (1) CA2247405C (ko)
CO (1) CO4780020A1 (ko)
CY (1) CY2293B1 (ko)
CZ (1) CZ291418B6 (ko)
DE (1) DE69713505T2 (ko)
DK (1) DK0906101T3 (ko)
EE (1) EE03511B1 (ko)
ES (1) ES2177942T3 (ko)
FR (1) FR2745500B1 (ko)
HK (1) HK1017999A1 (ko)
HU (1) HU227472B1 (ko)
IL (1) IL126050A (ko)
IN (1) IN187739B (ko)
NO (1) NO315841B1 (ko)
NZ (1) NZ331947A (ko)
OA (1) OA10854A (ko)
PL (1) PL189813B1 (ko)
PT (1) PT906101E (ko)
RU (1) RU2173997C2 (ko)
SK (1) SK282112B6 (ko)
TR (1) TR199801574T2 (ko)
TW (1) TW491711B (ko)
UA (1) UA49004C2 (ko)
WO (1) WO1997032584A1 (ko)
ZA (1) ZA971830B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
PT1322158E (pt) * 2000-10-02 2012-11-23 Usv Ltd Composições farmacêuticas de libertação prolongada contendo metformina e seu método de produção
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
CN104784180A (zh) 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
FR2745500A1 (fr) 1997-09-05
ATE219365T1 (de) 2002-07-15
IN187739B (ko) 2002-06-15
BG102692A (en) 1999-04-30
BG63451B1 (bg) 2002-02-28
HUP9902458A2 (hu) 2000-05-28
AU725494B2 (en) 2000-10-12
ES2177942T3 (es) 2002-12-16
CA2247405C (en) 2004-04-20
SK282112B6 (sk) 2001-11-06
JP2000512617A (ja) 2000-09-26
ZA971830B (en) 1997-09-04
PL328763A1 (en) 1999-02-15
EE03511B1 (et) 2001-10-15
EE9800275A (et) 1999-02-15
DE69713505D1 (de) 2002-07-25
EP0906101A1 (fr) 1999-04-07
AU1930097A (en) 1997-09-22
AR006082A1 (es) 1999-08-11
IL126050A0 (en) 1999-05-09
TW491711B (en) 2002-06-21
BR9707827A (pt) 1999-07-27
FR2745500B1 (fr) 1998-04-03
HK1017999A1 (en) 1999-12-10
TR199801574T2 (xx) 1998-11-23
CZ279198A3 (cs) 1999-01-13
CZ291418B6 (cs) 2003-03-12
CN1112929C (zh) 2003-07-02
RU2173997C2 (ru) 2001-09-27
CY2293B1 (en) 2003-07-04
PL189813B1 (pl) 2005-09-30
WO1997032584A1 (fr) 1997-09-12
NZ331947A (en) 2000-03-27
UA49004C2 (uk) 2002-09-16
HUP9902458A3 (en) 2002-11-28
US20050202089A1 (en) 2005-09-15
JP2007182451A (ja) 2007-07-19
EP0906101B1 (fr) 2002-06-19
SK121098A3 (en) 1999-01-11
DK0906101T3 (da) 2002-10-14
KR19990087387A (ko) 1999-12-27
CN1212624A (zh) 1999-03-31
DE69713505T2 (de) 2003-02-13
PT906101E (pt) 2002-09-30
CO4780020A1 (es) 1999-05-26
CA2247405A1 (en) 1997-09-12
NO984035L (no) 1998-10-22
NO984035D0 (no) 1998-09-02
IL126050A (en) 2004-05-12
KR100369888B1 (ko) 2003-05-17
HU227472B1 (en) 2011-07-28
NO315841B1 (no) 2003-11-03
US6165507A (en) 2000-12-26

Similar Documents

Publication Publication Date Title
EP0133110B1 (fr) Nouvelle composition pharmaceutique à base d'acide valproique et son procédé de fabrication
EP1051174B2 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
WO2005070398A2 (en) Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
KR100742432B1 (ko) 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
FR2759293A1 (fr) Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
EP1169032B1 (fr) Microgranules de ketoprofene, leur procede de preparation et compositions pharmaceutiques
JP2007182451A (ja) ミゾラスチンを含有する徐放性医薬製剤
EP1054672B1 (fr) Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
EP0868184B1 (fr) Microgranules a liberation prolongee contenant du diltiazem comme principe actif
FR2794646A1 (fr) Microgranules de sulfate de morphine, procede de preparation et composition les contenant
JP2002538197A (ja) ベタヒスチンの徐放性組成物
WO2022200402A1 (fr) Formulation par voie orale d'ivermectine et utilisations
JP4945043B2 (ja) モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
WO2011000518A1 (en) Pharmaceutical composition comprising desloratadine
WO2003057198A1 (fr) Compositions pharmaceutiques a liberation modifiee
EP1115399B1 (fr) Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques
MX2008007383A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
EP0412877A1 (fr) Nouvelle forme galénique orale améliorant la biodisponibilité
WO2000025749A1 (fr) Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques